Current Research

Research for eosinophilic leukemia and other myeloproliferative disorders is ongoing. The following advances may still be under investigation in clinical trials and may not be approved or available at this time. Always discuss all diagnostic and treatment options with your doctor.

Genetic research. Because this type of disorder is usually associated with a genetic mutation, researchers are searching for specific genetic markers (the presence or absence of specific genes or mutations that can indicate cancer).

Expanded use of transplantation. New approaches for stem cell/bone marrow transplantation are being tested.

New treatments. Better combinations of chemotherapy and additional treatment combinations are also being explored, as is the drug mepolizumab (Bosatria). Mepolizumab is a humanized monoclonal antibody that binds specifically to human interleukin 5 (hIL-5) and inhibits its activity. Preliminary studies in people have shown that mepolizumab lowers blood eosinophilia in people with allergies and HES and has alleviated some clinical signs and symptoms of HES.